Gilead Sciences

Biktarvy combines bictegravir with emtricitabine and tenofovir alafenamide into a single daily tablet from Gilead for HIV-1 infection. Bictegravir blocks the viral integrase enzyme, stopping HIV from inserting its genetic material into infected cells.

To multiply, HIV must insert its genetic code into the DNA of the immune cells it infects. An enzyme called integrase performs that insertion. Bictegr

Descovy combines emtricitabine with tenofovir alafenamide into a single daily tablet from Gilead for HIV-1 infection and for pre-exposure prophylaxis (PrEP) in people at risk. Both drugs block the viral reverse transcriptase enzyme, stopping HIV from copying its genetic material into new virus particles.

Emtricitabine and tenofovir alafenamide are two medicines that work together against HIV. Both are building-block look-alikes that the virus mistakes

Sunlenca (lenacapavir) is a first-in-class long-acting HIV-1 capsid inhibitor from Gilead for adults with multidrug-resistant HIV-1 infection who cannot otherwise build a suppressive regimen. It targets the virus's protective protein shell at multiple stages of the replication cycle and is given as a subcutaneous injection every six months.

Lenacapavir targets the capsid, the protein shell protecting HIV's genetic material. The capsid must be strong enough to shield the virus as it enters

Sacituzumab govitecan (Trodelvy) is an antibody-drug conjugate that targets Trop-2, a protein found on many cancer cells. It delivers a cancer-killing drug directly into those cells. It is used to treat certain types of breast cancer, including triple-negative and hormone receptor-positive breast cancers.

Sacituzumab govitecan is made of two parts: an antibody that finds cancer cells, and a cancer-killing drug attached to it. The antibody binds to a pro

Epclusa combines sofosbuvir and velpatasvir into a single daily tablet from Gilead for chronic hepatitis C virus (HCV) infection in adults and children aged 3 years and older. The two drugs block different steps the virus uses to copy itself, and the combination can cure HCV across all major genotypes.

Sofosbuvir and velpatasvir are two antiviral medicines that work together to cure chronic hepatitis C. Sofosbuvir blocks an enzyme called NS5B polymer